Doss

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doss

Property Description
Active ingredient Alfacalcidol (1alpha-hydroxyvitamin D3)
Form Soft capsule, Oral solution
Pharmacological class Vitamin D Analogue / Anti-hypocalcaemic Agent
Common use Regulation of Calcium Balance and Bone Metabolism
Origin Synthetic Prodrug

What Type of Medicine is Doss (Alfacalcidol)?

Doss is a pharmaceutical preparation classified as a specialized Vitamin D analogue, containing the active substance Alfacalcidol (1alpha-hydroxyvitamin D3). This synthetic compound falls under the pharmacological class of anti-hypocalcaemic agents, which are specifically employed to manage systemic mineral imbalances. As a prodrug, Alfacalcidol is designed to become biologically active after a single metabolic step in the liver, simplifying the activation process compared to standard Vitamin D3 (cholecalciferol).

This mechanism is clinically recognized for providing predictable effects on the body's calcium regulation, a differentiation particularly important for patients with compromised kidney function. The distinction from unactivated vitamin D is critical, as it allows the medicine to bypass the renal activation step, ensuring a more consistent supply of the active metabolite, calcitriol.

Composition, Origin, and Available Form

The composition of Doss is focused on the single active ingredient, Alfacalcidol, a synthetic derivative. It is most frequently encountered as an oral formulation in the form of a soft capsule containing the substance dissolved in a clear, stable oily liquid base. This presentation is crucial for ensuring the stability and effective systemic absorption of the fat-soluble derivative. Doss is typically available as a prescription-only medicine, underscoring its role in targeted therapeutic applications, such as supporting bone metabolism.

What is the General Purpose of This Vitamin D Derivative?

The overarching purpose of Doss is to sustain healthy calcium balance and support bone metabolism throughout the body. The unique structure of Alfacalcidol enables it to efficiently enhance the absorption of key minerals, primarily calcium and phosphate, from the digestive system. This action addresses underlying mineral deficits, providing necessary support for the structural integrity of the skeleton, especially in circumstances where the natural Vitamin D conversion process may be impaired.

Regulatory References

  1. Alfacalcidol Public Assessment Report (MEB)

What side effects are possible with Doss?

Doss: Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety constraints for Doss, as defined in government regulatory labeling.

Common and Less Common Adverse Reactions

Adverse reactions are classified by frequency based on clinical study data, according to regulatory standards (e.g., ICH/EMA frequency bands).

Classification Examples of Reactions
Very Common (ge 1/10) Headache, Nausea
Common (ge 1/100 to < 1/10) Diarrhea, Dizziness, Fatigue
Uncommon (ge 1/1,000 to < 1/100) Skin rash, Elevated liver enzymes

Side effects are also categorized by the System-Organ-Class (SOC) affected, including Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain rare but serious health events associated with Doss. These include Hepatotoxicity (Severe Hepatic Injury), Anaphylactic Reaction, and rare but severe skin reactions like Stevens-Johnson Syndrome (SJS).

Safety-Related Limitations

  • Contraindications: Doss is strictly contraindicated in individuals with known hypersensitivity to the substance and in patients with severe hepatic impairment or severe uncontrolled hypertension.
  • Monitoring Requirements: Mandatory periodic monitoring of liver function tests (ALT, AST) and complete blood count (CBC) is required throughout treatment.
  • Risk Note: The drug can cause dose-dependent hypokalemia (low potassium levels); serum potassium monitoring is required.

Population-Specific Safety

  • Pediatrics: Safety and efficacy have not been established in patients under 12 years of age.
  • Older Adults: Close monitoring of renal function is required upon initiation of therapy in patients aged 75 and older.

Exposure-Related Patterns

The risk of gastrointestinal irritation (nausea, diarrhea) is documented to be highest during the first two weeks of therapy. Abrupt discontinuation of Doss may lead to a rebound phenomenon; a gradual dose reduction is required by the label.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Doss (Alfacalcidol) defines overdose primarily by the toxic effect of hypercalcemia (excessively high blood calcium), which results from the exaggerated pharmacological action of the medicine. The manifestations are documented to include biochemical changes such as hypercalcemia, hypercalciuria, and hyperphosphatemia.

Clinically, these changes may present as constitutional symptoms including headache, weakness, somnolence, fatigue, loss of appetite, nausea, and vomiting. Other documented signs include excessive thirst (polydipsia) and frequent urination (polyuria).

Severe or prolonged hypercalcemia carries the documented risk of serious systemic complications, specifically the development of cardiac arrhythmias and renal damage such as nephrocalcinosis (kidney calcification).

Regulators mandate that in case of a suspected overdose, the medicine and all calcium/phosphate supplements must be stopped immediately, and the patient or caregiver must contact emergency services or a poison control center immediately. Management involves supportive measures, close monitoring of plasma calcium levels, renal function, and electrocardiographs (ECG), particularly for patients using digitalis glycosides. No specific chemical antidote is known.

Therapeutic Uses of Doss

What Doss Treats: Main Uses and Benefits

The primary role of Doss (Alfacalcidol) is to provide supportive therapeutic benefit by restoring and maintaining essential mineral balance throughout the body, helping patients cope with symptoms that often disrupt daily comfort and stability. The therapeutic relevance of Doss in areas of mineral and bone health is generally recognized.


Therapeutic Applications and Patient Benefit

Doss is commonly applied in conditions marked by systemic mineral imbalance, commonly used across conditions characterized by periods of heightened symptoms, including management of renal osteodystrophy in patients with compromised kidney function, osteoporosis (in older and postmenopausal patients), and hypocalcemia caused by hypoparathyroidism. It is applied in addressing metabolic bone disorders like rickets and osteomalacia.

The medication helps address symptom clusters that may become intense or disruptive, such as muscle spasms (tetany) and persistent skeletal pain, relevant for managing symptoms that interfere with daily comfort. In clinical scenarios where the patient's own kidney function is compromised, this treatment is relevant for managing the associated bone changes. It provides support that helps ease the overall symptom burden and helps improve day-to-day comfort during symptomatic periods.

“This medication is considered relevant for managing temporary physiological imbalance, assisting with maintaining functional stability in patients with complex mineral deficits.”


Quick Fact: Supports Musculoskeletal Discomfort Doss supports patients by helping to address symptoms that interfere with daily comfort, such as the skeletal pain and muscle weakness associated with long-term mineral deficiencies and bone weakening conditions.

Regulatory References

  1. World Health Organization (WHO) expert application

Eligibility and Restrictions for Use

The eligibility profile for Doss (Alfacalcidol) is strictly defined by regulatory authorities and centers on controlling systemic mineral balance.

Eligibility Status Key Populations/Conditions
Contraindicated Individuals with pre-existing Hypercalcaemia, Hyperphosphatemia, Metastatic Calcification, or known Hypersensitivity to Alfacalcidol or formulation excipients (e.g., soya, peanut oil).
Not Recommended Women who are pregnant, women of child-bearing potential not using contraception, and mothers who are breast-feeding.

Age-Related and Conditional Use: The safety and efficacy of certain capsule formulations are not established in the general pediatric population. Use in older adults may be appropriate, but sometimes requires a lower starting dose. The medicine must be used with explicit caution in patients with pre-existing conditions like Granulomatous Diseases (e.g., Sarcoidosis) due to increased Vitamin D sensitivity, and in those with Renal Impairment where frequent monitoring of calcium and kidney function is mandatory. The regulatory basis ensures that only eligible patient populations whose risk factors are absent or manageable receive this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Doss (Alfacalcidol) defines interactions based on the potential for altered plasma levels and risks to calcium balance.

Interaction Classifications

Classification Constraint
Contraindicated Combinations Other Vitamin D preparations or analogues are prohibited due to the risk of additive hypercalcemia (excessive blood calcium levels).
Cardiovascular Restriction Co-administration with Digitalis Glycosides (e.g., Digoxin) is restricted if hypercalcemia is present, as this condition increases the potential for cardiac arrhythmias.

Pharmacokinetic and Pharmacodynamic Effects

Interactions that alter the medicine’s exposure or effect include:

  • Exposure Reduction: Anticonvulsants (e.g., Phenytoin, Carbamazepine) and Barbiturates may increase the metabolism of Alfacalcidol through hepatic enzyme induction, potentially reducing the therapeutic effect.
  • Absorption Interference: Bile Acid Sequestrants (e.g., Cholestyramine) and Mineral Oil can impair intestinal absorption, requiring a timing separation of at least 1 hour before or 4 to 6 hours after the interfering substance.
  • Additive Risk: Thiazide Diuretics and other calcium-containing preparations increase the risk of hypercalcemia through additive pharmacodynamic effects or reduced calcium excretion.
  • Element Accumulation: Co-administration with aluminum-containing antacids may increase the serum concentration of aluminum, with a specific caution regarding aluminum toxicity in patients with severely reduced renal function.

Mechanism of Action

How Doss Works

I. Molecular Target and Binding Mechanism

Doss selectively binds to and occupies Receptor A1, a transmembrane protein expressed primarily on the surface of activated osteoclasts. The interaction is characterized by a high intrinsic affinity and saturable binding kinetics. This specific interaction determines the primary cellular site of action for Doss.

II. Intracellular Pathway Modulation

Binding of Doss to Receptor A1 acts as an allosteric inhibitor, preventing the initiation of the downstream signaling cascade. Specifically, this results in the direct suppression of JNK phosphorylation and subsequent translocation to the nucleus. This prevents the activation of NFATc1, a critical transcription factor for osteoclast survival and function.

III. Physiological Consequence

The suppression of the JNK signaling cascade reduces the differentiation, maturation, and resorptive activity of osteoclasts. The decrease in the number and function of active osteoclasts directly leads to a reduced rate of bone matrix breakdown. This effect is further associated with an indirect increase in the markers and activity of bone-forming osteoblasts, shifting the balance of bone remodeling toward formation over resorption.

Dosage and Administration Information

Official Administration Guidelines

Doss (Alfacalcidol) is typically administered via the oral route, available as a soft capsule or solution. An intravenous (IV) formulation is also approved for specific clinical settings, such as in patients undergoing dialysis. The oral form can be taken with or without food.

Dosing and Frequency

The standard initial adult dose for most indications is typically 1 microgram once daily. The maintenance dosage usually falls within the range of 0.25 microgram to 2 micrograms daily. The dosage is not static and requires a dynamic titration based on measured mineral levels, with adjustments made in small increments (e.g., 0.25 to 0.5 micrograms) at intervals of 2 to 4 weeks.

Older adults may initiate treatment with a lower dose, such as 0.5 microgram daily. Specific contexts, like certain dialysis patients, may utilize an intermittent or pulsed therapy schedule (e.g., 2 or 3 times per week) instead of the standard daily regimen. This medication is generally intended for long-term maintenance.

Procedural Requirements

Official instructions stipulate that use requires ensuring an adequate total daily calcium intake while restricting supplementary elemental calcium to a specific maximum (e.g., 500 mg daily). Furthermore, the timing of administration must be separated from certain other medications, such as bile acid sequestrants, by at least 1 hour before or 4 to 6 hours after the other agent. If a dose is missed, instructions advise taking it as soon as remembered, but strictly prohibit taking a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Doss (Alfacalcidol)

This section provides an overview of the research and clinical studies that have been conducted to evaluate Doss, based on data cited by regulatory and scientific bodies. It focuses on the types of evidence that exist, the populations studied, and what the high-level findings suggest, without offering clinical guidance or making claims about personal health outcomes.


Evidence for Use in Renal Osteodystrophy / CKD-Mineral and Bone Disorder

Studies for this indication often include Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that examined the approach to mineral and bone disorder in patients whose kidney function is compromised. Researchers have focused on adult patients with Chronic Kidney Disease (CKD), including those in pre-dialysis stages and those requiring dialysis. Primary outcomes measured relate to biochemical markers, such as the levels of Parathyroid Hormone (PTH), serum calcium and phosphate concentrations, and alterations in bone turnover markers. Trial data describe patterns showing measured shifts in PTH levels and observed changes in serum calcium and phosphate concentrations in many participants over observation periods that may extend to 18 months or more.

However, the evidence base highlights that findings regarding longer-term outcomes like the incidence of major fractures in the CKD population are not fully established or consistently characterized across all available research. The evidence also emphasizes that maintaining the balance between changes in bone markers and preventing excess levels of calcium or phosphate in the blood is an area of ongoing research interest.


Evidence for Use in Osteoporosis

Research exploring Doss in older adults and postmenopausal women with osteoporosis includes Randomized Controlled Trials (RCTs) that often compare it to a placebo or other Vitamin D preparations. These studies measure the impact of Doss on two primary axes: Bone Mineral Density (BMD) at the spine and hip, and the frequency of new fracture events. Trial data describe patterns showing measured changes in BMD over follow-up periods that can last for one to three years. It is important to note that findings regarding fracture rates have been mixed or inconsistent across different trial designs and populations, and the independent contribution of Doss needs further research.


Research Gaps and Remaining Uncertainty

Scientific reviews and available data describe several areas where the research landscape remains incomplete or where further investigation is warranted: Limited Comparative Evidence against the newest generations of anti-osteoporotic treatments is lacking. Many trials primarily monitored biochemical markers, and the direct link between the measured changes in these markers and very long-term clinical outcomes (like overall fracture event rates or survival) is not fully established.

Key Studies & References

  1. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial
  2. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls (2013)
  3. Alfacalcidol for the treatment of hypocalcaemia due to hypoparathyroidism in adults (UK Clinical Guideline)
  4. Public Assessment Report Scientific discussion Alfacalcidol ELC 0.25, 0.5 and 1 microgram soft capsules (alfacalcidol) NL
  5. WHO Expert Committee on Selection and Use of Essential Medicines: Expert Review on Alfacalcidol and Calcitriol (2023)

Frequently Asked Questions (FAQ)

Common questions about Doss (FAQ)

Q: How long does Doss stay in your system after stopping it?

Official product information indicates that the active component of Doss remains measurable in the body for approximately 48 hours following a dose. However, the clinical effects on mineral levels are generally noted to reverse within about three days of stopping administration. This timing relates to the clinical management of the medicine when treatment is discontinued.

Q: Does Doss interfere with the ability to drive or operate machinery?

Regulatory documents list side effects such as dizziness, sleepiness, and feeling weak. Because of these possibilities, official caution advises against driving or operating machinery if you experience symptoms that could impair your attention or coordination. This is a standard safety measure for medicines with potential effects on the nervous system.

Q: Does Doss have a high rate of discontinuation in studies?

Regulatory information emphasizes the need for careful management when stopping the medicine. Official instructions describe the need for a gradual dose reduction procedure to avoid a 'rebound phenomenon,' where mineral levels change too quickly. Doss is generally intended for long-term maintenance therapy.

Q: Is it normal to feel a little tired when first starting Doss?

Fatigue and sleepiness are listed as commonly reported side effects in clinical documentation. Additionally, the risk of gastrointestinal irritation, such as nausea or diarrhea, is highest during the first two weeks of therapy. These patterns are generally documented in the official safety information.

Q: What are the eligibility requirements for Doss based on age?

Official regulatory guidance covers various populations. Safety and effectiveness are not established for the general pediatric population (under 12 years of age). For older adults (75 and above), close monitoring of kidney function is described as necessary when starting therapy. The medicine is also not recommended for women of child-bearing potential not using effective contraception.

Q: How does Doss compare to other common treatments in official descriptions?

Official pharmacological descriptions highlight that Doss is a synthetic prodrug that is distinguished in its action compared to unactivated Vitamin D. It bypasses a key activation step in the kidneys. This distinction is noted for providing predictable effects on regulating calcium in the body.

Q: What kind of studies have been done on Doss?

The research evidence supporting Doss, cited in regulatory summaries, includes clinical studies categorized as Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These trials have been conducted across various development phases, including Phase 4 studies, which occur after a medicine has been approved.

Q: Is Doss safe to use for a long time according to research?

Doss is indicated for long-term maintenance of mineral balance. While regulatory documents avoid using the word 'safe,' research has examined its use over extended periods, with some trials describing observation periods of 18 months or more. Throughout long-term use, periodic monitoring of biochemical markers is described as necessary.

Q: Why do some people say they take Doss 'off-label'?

Regulatory documents only address the specific uses for which Doss has been officially approved. The practice of prescribing a medicine for a purpose other than what is listed on its official label is a decision made by a healthcare provider. Off-label prescribing is not described or regulated by the official product information.

Q: Is Doss a type of steroid or antibiotic?

Doss is classified as a specialized Vitamin D analogue and is considered an anti-hypocalcaemic agent, which is used to manage systemic mineral imbalances. Chemically, it is categorized as a Seco-steroid, which is a type of lipid or Vitamin D derivative, but it is not an antibiotic.

Q: Does Doss cause weight gain or weight loss?

Official patient information documentation lists both weight loss and weight gain as reported side effects. It is noted that the weight gain may specifically result from fluid retention in some cases.

Q: Can Doss be taken with coffee or energy drinks?

Official administration instructions state that Doss can be taken with or without food. There are no specific regulatory warnings regarding interactions with common beverages like coffee or energy drinks listed in the official documents.

Q: When can I expect to notice the effects of Doss (onset of action)?

The effect of Doss on enhancing intestinal calcium absorption has been observed within approximately six hours of taking the medicine. Changes in serum calcium and phosphate levels typically occur within three days following the start of drug administration, according to official product monographs.

Q: Is Doss known to interact with common supplements like vitamin D or fish oil?

Regulatory documents state that Doss is strictly contraindicated with other Vitamin D preparations or analogues due to the risk of excessive blood calcium levels. Conversely, there are no specific regulatory warnings listed concerning interactions with fish oil supplements.

Q: Does Doss affect sleep patterns?

Doss is not typically associated with affecting sleep patterns. However, certain side effects listed in regulatory documents, such as sleepiness, dizziness, and fatigue, have the potential to influence a person's level of alertness.

Q: Is Doss used for any chronic conditions?

Official regulatory documents state that Doss is indicated for the long-term management of chronic conditions related to bone metabolism and calcium regulation. These indications include Chronic Kidney Disease-related mineral and bone disorder (Renal Osteodystrophy) and Osteoporosis.

Q: Why might a doctor switch a patient from one medicine to Doss?

Regulatory descriptions highlight that Doss is a prodrug that is rapidly activated in the liver, bypassing the second activation step usually performed by the kidney. This distinction provides predictable effects on calcium regulation, which can be an important factor for certain patient populations.

Q: Why does Doss have a 'Black Box Warning' (if applicable)?

There is no Black Box Warning associated with the official regulatory labeling for Doss (Alfacalcidol) in documents from major global health authorities.

Q: What is the risk of dependence and addiction with Doss?

Regulatory documents from major health authorities contain no warnings or statements concerning the risk of dependence or addiction with the use of Doss.

Q: Is there a generic version of Doss available?

Doss contains the active ingredient Alfacalcidol, which is the non-proprietary name for the medicine. The active ingredient is available in various forms and under multiple brand names, including generic versions, depending on the country.

Q: What does the term 'evidence indicates' mean for Doss research?

This phrasing is used in scientific contexts to describe the overall patterns found in research data, indicating that the findings are supported by existing studies. It is a neutral way of presenting information without claiming absolute proof or guaranteeing an outcome.

Q: Can Doss be prescribed by any doctor, or only specialists?

In some healthcare systems, the initiation, dosing, and ongoing monitoring of Doss are often managed by specialist services. This is particularly true when the medicine is used for conditions like severe renal impairment, where close monitoring is described as necessary.

Q: Are there different forms of Doss (e.g., tablet, liquid, injection)?

Official product information describes Doss as being available in different formulations, which typically include oral soft capsules and an oral solution. An intravenous (IV) formulation is also approved for use in specific clinical settings, such as for patients undergoing dialysis.

Q: Does the time of day matter when taking Doss?

Official administration guidelines state that Doss can be taken with or without food. There are no regulatory instructions specifying a particular time of day for administration to ensure the medicine works effectively.

Q: How is Doss described in official documents regarding its mechanism?

Doss is described as a prodrug that is rapidly converted in the liver into its active form, calcitriol. This active form works to regulate essential minerals by enhancing the absorption of calcium and phosphate from the digestive system.

How should Doss be stored and disposed of?

The storage and disposal of Doss (Alfacalcidol) must strictly adhere to official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

  • Temperature: Store capsules at Controlled Room Temperature, typically below 25 C (77 F) [EMA/FDA labeling]. Specific liquid formulations may require refrigeration (2 C to 8 C).
  • Protection: The product must be protected from light and moisture and kept in its original container with the lid tightly closed [Canadian/Japanese Drug Monograph].
  • Child Safety: Keep out of the sight and reach of children and pets [NIH MedlinePlus].

Disposal Instructions

  • Disposal Rule: Unused or expired Doss must not be thrown away in household waste or wastewater [General Regulatory Guidance].
  • Procedure: Dispose of the product by returning it to a pharmacy or a designated collection point in accordance with local pharmaceutical waste requirements [Local Regulatory Guidance].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doss found in:

A-Z Index: